Regulation of RAGE for attenuating progression of diabetic vascular complications

Exp Diabetes Res. 2012:2012:894605. doi: 10.1155/2012/894605. Epub 2011 Oct 29.

Abstract

Diabetic angiopathy including micro- and macroangiopathy is concerned with high rate of morbidity and mortality in patients with long-standing diabetes. Receptor for advanced glycation end products (RAGE) and its ligands have been considered as important pathogenic triggers for the progression of the vascular injuries in diabetes. The deleterious link between RAGE and diabetic angiopathy has been demonstrated in animal studies. Preventive and therapeutic strategies focusing on RAGE and its ligand axis may be of great importance in relieving diabetic vascular complications and reducing the burden of disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Atherosclerosis / etiology
  • Diabetic Angiopathies / drug therapy
  • Diabetic Angiopathies / etiology
  • Diabetic Angiopathies / prevention & control*
  • Diabetic Nephropathies / etiology
  • Diabetic Neuropathies / etiology
  • Glycation End Products, Advanced / antagonists & inhibitors
  • Glycation End Products, Advanced / physiology
  • Humans
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic / antagonists & inhibitors
  • Receptors, Immunologic / physiology*

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products
  • Receptors, Immunologic